Jul 31, 2021 01:27 PM IST
His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."
- May 21, 2021 08:59 AM IST
Gland Pharma’s revenue growth surpassed that of frontline drug companies in FY21. It is expected to outpace industry majors in the current fiscal too
- Feb 25, 2021 12:47 PM IST
In October 2020, India and South Africa submitted a proposal suggesting a waiver for all WTO (World Trade Organisation) members on the implementation, application and enforcement of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.
- Feb 23, 2021 05:45 PM IST
Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows.
- Jan 21, 2021 03:21 PM IST
Given the government’s ambition to make India a $5 trillion economy in the next five years, pharmaceutical and life science could be the ‘target sector’ in Budget 2021
- Mar 12, 2020 06:28 PM IST
The notification has been sent to the Central Pollution Control Board, Expert Appraisal Committee and pollution control boards in all states and Union territories.
- Mar 05, 2020 07:37 PM IST
Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand what it means for the Indian pharma industry.
- Jan 28, 2020 03:35 PM IST
The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access, Icra said in a statement.
- Jan 24, 2020 05:05 PM IST
Shraddha Sharma gets in conversation with Corporate Bureau Chief Prince Thomas to find out the expectations of the phama sector from Finance Minister Nirmala Sitharaman in Budget 2020.
- May 17, 2017 09:19 PM IST
“These companies have launched formulations by altering a scheduled formulation with strength/dosage other than as specified in DPCO, 2013 and secondly in combination with other non-scheduled medicines without even applying for price approval from NPPA as required under Para 1 (2) of DPCO, 2013,” NPPA said.
- May 14, 2017 03:21 PM IST
Here's what happened in pharma last week
- Jan 24, 2017 04:29 PM IST
R&D/clinical trial services performed in India are liable to service tax at the rate of 15% even when the recipient of service is situated outside India. To lower the cost of provision of such services and to boost innovation in the country and make such services globally competitive, it is important to provide for some sort of exemption.
- Nov 07, 2016 07:58 PM IST
A Democrat sweep in US polls may
pose even greater pricing challenges for the pharma industry
and pave the way for tighter pricing regulations for both
brand name and generic drugs, according to a report.
- Nov 26, 2015 09:47 PM IST
The Central Board Of Direct Taxation (CBDT) has now extended the time period for consultation to December 31.
- May 30, 2013 06:28 PM IST
With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, the ICRA report said.
- Dec 27, 2012 10:29 PM IST
2012 was occupied by Pharma industry bodies & patient groups debated over the contours of the pricing policy. Essential drugs are getting cheaper. The Pharma pricing policy that was drafted towards the end of 2011 was just the tip of the iceberg which melted into a veritable deluge.
- Apr 03, 2012 10:17 PM IST
The pharma industry is on the edge of its seat with all eyes on the April 4 Group of Ministers (GoM) meeting which will decide on a final pricing policy for essential drugs, reports CNBC-TV18's Archana Shukla.
- Jan 06, 2012 02:53 PM IST
Union health ministry's plan to bring 348 drugs of the National List of Essential Medicines (NLEM) under price control is facing stiff resistance from the pharma industry, reports the Times of India.
- Jul 19, 2011 08:25 PM IST
Pfizer, the Indian unit of drug maker Pfizer Inc, is eyeing a 13-14% growth in its revenues in the financial year 2011-12, a senior company official said today.